Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial.
Rosás-Umbert M, Ruiz-Riol M, Fernández MA, Marszalek M, Coll P, Manzardo C, Cedeño S, Miró JM, Clotet B, Hanke T, Moltó J, Mothe B, Brander C; BCN02 study group. Rosás-Umbert M, et al. Among authors: hanke t. Front Immunol. 2020 Mar 20;11:418. doi: 10.3389/fimmu.2020.00418. eCollection 2020. Front Immunol. 2020. PMID: 32265913 Free PMC article. Clinical Trial.
A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
Wee EG, Patel S, McMichael AJ, Hanke T. Wee EG, et al. Among authors: hanke t. J Gen Virol. 2002 Jan;83(Pt 1):75-80. doi: 10.1099/0022-1317-83-1-75. J Gen Virol. 2002. PMID: 11752703
The minimum requirement for candidate human immunodeficiency virus (HIV) vaccines to enter clinical evaluation in humans should be their demonstrable immunogenicity in non-human primates: induction of antibodies neutralizing primary HIV isolates or elicitation of broad T c …
The minimum requirement for candidate human immunodeficiency virus (HIV) vaccines to enter clinical evaluation in humans should be their dem …
Development of a DNA-MVA/HIVA vaccine for Kenya.
Hanke T, McMichael AJ, Mwau M, Wee EG, Ceberej I, Patel S, Sutton J, Tomlinson M, Samuel RV. Hanke T, et al. Vaccine. 2002 May 6;20(15):1995-8. doi: 10.1016/s0264-410x(02)00085-3. Vaccine. 2002. PMID: 11983261 Review.
Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.
Rosario M, Hopkins R, Fulkerson J, Borthwick N, Quigley MF, Joseph J, Douek DC, Greenaway HY, Venturi V, Gostick E, Price DA, Both GW, Sadoff JC, Hanke T. Rosario M, et al. Among authors: hanke t. J Virol. 2010 Jun;84(12):5898-908. doi: 10.1128/JVI.02607-09. Epub 2010 Apr 7. J Virol. 2010. PMID: 20375158 Free PMC article.
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.
Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, Ammendola V, Ljungberg K, Borthwick N, Im EJ, McMichael AJ, Drijfhout JW, Greenaway HY, Venturi V, Douek DC, Colloca S, Liljeström P, Nicosia A, Price DA, Melief CJ, Hanke T. Rosario M, et al. Among authors: hanke t. Eur J Immunol. 2010 Jul;40(7):1973-84. doi: 10.1002/eji.201040344. Eur J Immunol. 2010. PMID: 20468055 Free article.
439 results